Eptifibatide Injection
Product Images NDC 55150-218

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Eptifibatide (NDC 55150-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Kaplan-meier Plot Of Time To Death Or Myocardial Infarction Within 30 Days Of Randomization In The Pursuit Study (Eptifibatide Fig1)

Figure 1: Kaplan-meier Plot Of Time To Death Or Myocardial Infarction Within 30 Days Of Randomization In The Pursuit Study (Eptifibatide Fig1)
Not available.*
FDA Label Image

Package Label-principal Display Panel (75 mg per 100 mL (0.75 mg / mL))

Package Label-principal Display Panel (75 mg per 100 mL (0.75 mg / mL))
Eptifibatide is an injection medication provided in a 100 mL single-dose vial, with a concentration of 0.75 mg/mL. It is intended for use under prescription only and must be kept sterile, preservative-free and stored between 2° to 8°C (36° to 46°F), or transferable to 25°C (77°F) for up to 2 months in a USP controlled environment. The medication contains Sodium Hydroxide and is distributed by AuroMedics Pharma LLC from E. Windsor, NJ. The dosage should follow an accompanying package insert and any unused medication should be discarded.*
FDA Label Image

Package Label-principal Display Panel (75 mg per 100 mL (0.75 mg / mL))

Package Label-principal Display Panel (75 mg per 100 mL (0.75 mg / mL))
This is a product description for a single-dose vial of Eptifibatide injection, with 75mg per 100mL (0.75mg/mL), manufactured in India by TS/DRUGS/13/2010, and distributed by AuroMedics Pharma LLC in East Windsor, NJ. The vial stoppers are not made with natural rubber latex. The solution is sterile, non-pyrogenic, and preservative-free, and should be discarded if unused. The recommended storage temperature is 2°C to 8°C (36°F to 46°F), but may be transferred to 25°C (77°F) for a maximum of 2 months. The product is for intravenous use only and must be protected from light until administration. Dosage information is included in the package insert.*
FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg / mL))

Package Label-principal Display Panel (20 mg per 10 mL (2 mg / mL))
This is a prescription medication in a 10mL single-dose vial. It is sterile, non-pyrogenic, and preservative-free. The contents are not specified, but the instructions advise checking the outer carton. The recommended dosage and storage instructions are also provided. The medication should be stored in a cool place, and can be stored for up to two months at a slightly higher temperature before use. The medication is for intravenous use only, and should be discarded if any portion remains unused. The manufacturer is AuroMedics Pharma LLC.*
FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg / mL))

Package Label-principal Display Panel (20 mg per 10 mL (2 mg / mL))
This is a description of a medication, "Eptifibatide Injection". It contains 20 mg of eptiibatide in a 10 mL single-dose vial for intravenous use only. It is used for weight-adjusted bolus dosing and should be discarded if not used within 2 months of transfer. The medication is distributed by AuroMedics Pharma LLC and made in India. The storage temperature is between 2°C to 8°C and it can be transferred to 25°C for up to 2 months. It contains citric acid, sodium hydroxide, and water for injection. Usual dosage should be referred to the accompanying package insert. It is sterile, non-pyrogenic, and preservative-free. The via stoppers are not made with natural rubber latex. The code printed on it is TS/DRUGS/13/2010, and the NDC number is 55150-219-10.*
FDA Label Image

Package Label-principal Display Panel (200 mg per 100 mL (2 mg / mL))

Package Label-principal Display Panel (200 mg per 100 mL (2 mg / mL))
This is a description for a medication called Eptifibatide manufactured by AuroMedics. It is a non-pyrogenic, preservative-free, sterile solution containing 2 mg of Eptifibatide per mL. The solution is adjusted to a pH of 5.35 using Sodium Hydroxide and comes in a single-use vial of 100 mL. The usual dosage and storage instructions are given, and the medication is distributed in the USA by AuroMedics Pharma LLC. The code number TYDRUGS/13:2010 is also present.*
FDA Label Image

Package Label-principal Display Panel (200 mg per 100 mL (2 mg / mL))

Package Label-principal Display Panel (200 mg per 100 mL (2 mg / mL))
This is a description of a medication called Eptifibatide in a 100mL single-dose vial for intravenous use only. The medication is sterile, non-pyrogenic, and preservative-free. Each mL of the contents contains 2 mg epifibatide and 5.25 mg citric acid in water for injection, with a pH of 5.35. The normal dosage is mentioned in the package insert. The medication is manufactured in India and distributed by AuroMedics Pharma LLC in NJ, USA. It is advised to store the medication in a refrigerator at a temperature of 2° to 8°C (36° to 46°F) and protect it from light until administration. If the medication is not used within 2 months of transfer, it must be discarded.*
FDA Label Image

Eptifibatide Chemical Structure (Eptifibatide Str)

Eptifibatide Chemical Structure (Eptifibatide Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.